News & Press Releases Archives

Press Releases

05/25/2017
KPI Therapeutics Presents New Dalazatide Data Again Demonstrating Positive Response in Lupus
Learn More »
04/27/2017
KPI Therapeutics Presents Updated, Positive Data Demonstrating Efficacy of KPI-150 Against Atopic Dermatitis
Learn More »
04/05/2017
KPI Therapeutics Nominated for the Buzz of Bio for its Promising Pipeline
Learn More »
02/28/2017
KPI Therapeutics Will Present New, Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Upcoming Skin Disease Conference
Learn More »
01/03/2017
KPI Therapeutics to Give Corporate Update at Biotech Showcase Investor Conference during JP Morgan Week
Learn More »
11/16/2016
KPI Therapeutics Presents New Positive Data Demonstrating Efficacy of KPI-150 Against Atopic Dermatitis
Learn More »
10/27/2016
KPI Therapeutics Invited to Present Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Skin Disease Conference
Learn More »
10/11/2016
KPI Therapeutics Invited to Provide a Corporate Update at BIO Investment Conference in San Francisco
Learn More »
9/20/2016
Dr. Chelsea Olsen Promoted to Vice President Scientific Affairs at KPI Therapeutics
Learn More »
6/20/2016
Dalazatide as a Potential Immunotherapy for Lupus to be Presented at Immunology Conference
Learn More »
6/10/2016
Alliance for Children’s Therapeutics (ACT) Presents Dalazatide Data Demonstrating Positive Response in Lupus
Learn More »
6/2/2016
KPI Therapeutics’ BIO Presentation to Highlight First Clinical Development Success of Kv 1.3 Inhibitor Dalazatide in Autoimmune Diseases
Learn More »
5/23/2016
KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus
Learn More »
5/17/2016
KPI Therapeutics to Give Company Presentation at BIO Annual Industry Conference
Learn More »
5/12/2016
KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference
Learn More »
5/11/2016
KPI Therapeutics' Non-Opiate Pain Drug Effective in Neuropathic Pain and Burn Pain
Learn More »
4/18/2016
KPI Therapeutics to Present Dalazatide Plaque Psoriasis Data at Dermatology Conference
Learn More »
3/21/2016
KPI Therapeutics Presents Promising Data on KPI-190 as Potential Therapy for Uveitis, Autoimmune Eye Diseases
Learn More »
3/14/2016
KPI Therapeutics to Present Dalazatide Data as Potential Therapy for Uveitis, Autoimmune Eye Diseases at Ocular Conference
Learn More »
2/8/2016
KPI Therapeutics Invited to Present at BioCentury Future Leaders Investment Conference
Learn More »
2/8/2016
KPI Therapeutics Announces Expanded Drug Programs in Eye and Skin Diseases
Learn More »
2/3/2016
KPI Invited to Present at BIO CEO & Investor in NYC
Learn More »
1/11/2016
KPI to Present at Biotech Showcase Conference during JP Morgan Week
Learn More »
4/21/2015
University of Washington, Kineta, KPI form alliance to advance discoveries to bring new therapeutics to market
Learn More »
6/05/2014
Biotech Consortium Launches KPI Therapeutics, Inc., a New Collaborative Initiative to Speed Drug Development and Improve Investor Outcomes
Learn More »

« Back to Press Releases


KPI in the News

3/8/2017
Dalazatide featured in National TV healthcare story
Learn More »
9/15/2016
Arthritis Research Foundation Video Highlights Dalazatide
Learn More »
8/2016
Lupus drug moves forward, DDNEWS
Learn More »
6/16/2016
Dalazatide Shows Promise in Early Lupus Study, Lupus News Today
Learn More »
6/2016
angelMD: Getting to Know KPI
Learn More »
6/10/2016
Sea Anemone Venom Shows Promise For Lupus Immunotherapy Treatment
Learn More »
4/13/2016
Special Report on Neuroscience: Ease the pain, DDNews
Learn More »
2/23/2016
Seattle autoimmune biotech KPI plans clinical trials, looks to raise $25M, Puget Sound Business Journal
Learn More »
2/2016
It’s a Long Road for Biopharma Company Leaders, with Challenges at Every Turn, Thomson Reuters
Learn More »
2/18/2016
Story on addiction and KPI conopeptide program, King 5
Learn More »
5/22/2015
Kineta and partners raising funds to 'break out of the old biotech model', GeekWire
Learn More »
4/21/2015
Seattle biotech teams with UW to ramp up drug discoveries, Puget Sound Business Journal
Learn More »
6/6/2014
Collaborative KPI Therapeutics launches to beef up Kineta's pipeline, FierceBiotech
Learn More »
6/05/2014
Seattle's Kineta helps launch investment group to speed drug development, Puget Sound Business Journal
Learn More »

« Back to KPI News


Development Partner News Releases

11/23/2015
Dalazatide shows potential in preclinical lupus study
Learn More »
11/10/2015
Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus
Learn More »
9/21/2015
Kineta Chief Scientist to Speak on Dalazatide Clinical Results, Potential Therapy for Autoimmune Diseases at Basel Life Science Week
Learn More »
8/8/2015
Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation
Learn More »
7/7/2015
Kineta Presents New Data from its Non-Opiate Pain Drug Program
Learn More »
5/5/2015
Novel Drug From Nature Shows Early Promise, Wall Street Journal
Learn More »
5/05/2015
Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases
Learn More »
3/19/2015
Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
Learn More »

« Back to Partner News